Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Successful realisation of a fully automated endoscope cleaning system.

The Journal of hospital infection·2026
Same author

Aging-dependent skin microbiome alterations across body sites in a United Kingdom cohort.

Frontiers in aging·2025
Same author

Opportunities for microbiology citizen science: lessons learnt from three pilot projects.

Access microbiology·2025
Same author

Author Correction: An abundant ginger compound furanodienone alleviates gut inflammation via the xenobiotic nuclear receptor PXR in mice.

Nature communications·2025
Same author

An abundant ginger compound furanodienone alleviates gut inflammation via the xenobiotic nuclear receptor PXR in mice.

Nature communications·2025
Same author

Comparative Effectiveness of 2 Chlorhexidine Gluconate-Containing Dressings in Reducing Central Line-Associated Bloodstream Infections, Hospital Stay, and Costs.

Inquiry : a journal of medical care organization, provision and financing·2023

Related Experiment Video

Updated: Jul 7, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Thiosemicarbazones active against Clostridium difficile.

Cait Costello1, Tarja Karpanen, Peter A Lambert

  • 1School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK.

Bioorganic & Medicinal Chemistry Letters
|February 5, 2008
PubMed
Summary
This summary is machine-generated.

Researchers synthesized furylidene thiosemicarbazones and tested their effectiveness against Gram-positive bacteria. A specific compound demonstrated significant potential in combating Clostridium difficile infections.

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Related Experiment Videos

Last Updated: Jul 7, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Area of Science:

  • Medicinal Chemistry
  • Microbiology
  • Bacteriology

Background:

  • Antibiotic resistance is a growing global health concern, necessitating the development of novel antimicrobial agents.
  • Gram-positive bacteria, including Clostridium difficile, are significant causes of hospital-acquired and community-acquired infections.
  • Thiosemicarbazones represent a class of compounds with diverse biological activities, including antimicrobial properties.

Purpose of the Study:

  • To synthesize and characterize a series of furylidene thiosemicarbazone derivatives.
  • To evaluate the in vitro antimicrobial activity of these compounds against clinically relevant Gram-positive bacteria.
  • To identify specific structural features that contribute to potent antibacterial activity, particularly against Clostridium difficile.

Main Methods:

  • Synthesis of furylidene thiosemicarbazone analogs using established organic chemistry protocols.
  • Broth microdilution assays to determine the minimum inhibitory concentrations (MICs) against a panel of Gram-positive bacteria.
  • Structure-activity relationship (SAR) analysis to correlate chemical structure with observed antimicrobial potency.

Main Results:

  • A library of closely related furylidene thiosemicarbazones was successfully synthesized and characterized.
  • Screening revealed varying degrees of activity against tested Gram-positive bacteria.
  • One compound, featuring an ethylene spacer and a 5-nitrofuryl moiety, exhibited notable inhibitory activity against Clostridium difficile.

Conclusions:

  • Furylidene thiosemicarbazones are a promising scaffold for the development of new antibacterial agents.
  • The presence of an ethylene spacer and a 5-nitrofuryl group appears crucial for potent activity against Clostridium difficile.
  • Further investigation and optimization of these compounds are warranted for potential therapeutic applications against C. difficile infections.